Cargando…

Iron overload across the spectrum of non‐transfusion‐dependent thalassaemias: role of erythropoiesis, splenectomy and transfusions

Non‐transfusion‐dependent thalassaemias (NTDT) encompass a spectrum of anaemias rarely requiring blood transfusions. Increased iron absorption, driven by hepcidin suppression secondary to erythron expansion, initially causes intrahepatic iron overload. We examined iron metabolism biomarkers in 166 N...

Descripción completa

Detalles Bibliográficos
Autores principales:	Porter, John B., Cappellini, Maria Domenica, Kattamis, Antonis, Viprakasit, Vip, Musallam, Khaled M., Zhu, Zewen, Taher, Ali T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2016
Materias:	Red Cells and Iron
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5248634/ https://www.ncbi.nlm.nih.gov/pubmed/27917462 http://dx.doi.org/10.1111/bjh.14373

Ejemplares similares

Treating iron overload in patients with non-transfusion-dependent thalassemia
por: Taher, Ali T, et al.
Publicado: (2013)

Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload
por: Taher, Ali, et al.
Publicado: (2009)

Psychometric evaluation of the NTDT-PRO questionnaire for assessing symptoms in patients with non-transfusion-dependent beta-thalassaemia
por: Taher, Ali T, et al.
Publicado: (2023)

Deferasirox effectively reduces iron overload in non-transfusion-dependent thalassemia (NTDT) patients: 1-year extension results from the THALASSA study
por: Taher, Ali T., et al.
Publicado: (2013)

Erythroferrone exacerbates iron overload and ineffective extramedullary erythropoiesis in a mouse model of β-thalassemia
por: Olivera, Joseph, et al.
Publicado: (2023)

Vasculo‐toxic and pro‐inflammatory action of unbound haemoglobin, haem and iron in transfusion‐dependent patients with haemolytic anaemias
por: Vinchi, Francesca, et al.
Publicado: (2021)

Approaching low liver iron burden in chelated patients with non-transfusion-dependent thalassemia: the safety profile of deferasirox
por: Taher, Ali T, et al.
Publicado: (2014)

Epistasis and the sensitivity of phenotypic screens for beta thalassaemia
por: Penman, Bridget S, et al.
Publicado: (2015)

A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease
por: Vichinsky, Elliott, et al.
Publicado: (2007)

Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with nontransfusion-dependent thalassemia syndromes
por: Taher, Ali T, et al.
Publicado: (2016)

Long-term safety and efficacy of deferasirox (Exjade®) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease
por: Vichinsky, Elliott, et al.
Publicado: (2011)

When to consider transfusion therapy for patients with non-transfusion-dependent thalassaemia
por: Taher, A T, et al.
Publicado: (2015)

Haptoglobin, alpha‐thalassaemia and glucose‐6‐phosphate dehydrogenase polymorphisms and risk of abnormal transcranial Doppler among patients with sickle cell anaemia in Tanzania
por: Cox, Sharon E., et al.
Publicado: (2014)

Identification and key management of non-transfusion-dependent thalassaemia patients: not a rare but potentially under-recognised condition
por: Viprakasit, Vip, et al.
Publicado: (2014)

Luspatercept for transfusion-dependent β-thalassemia: time to get real
por: Musallam, Khaled M., et al.
Publicado: (2023)

An activin receptor IIA ligand trap promotes erythropoiesis resulting in a rapid induction of red blood cells and haemoglobin
por: Carrancio, Soraya, et al.
Publicado: (2014)

Human induced pluripotent stem cell derived erythroblasts can undergo definitive erythropoiesis and co-express gamma and beta globins
por: Yang, Cheng-Tao, et al.
Publicado: (2014)

2021 Thalassaemia International Federation Guidelines for the Management of Transfusion-dependent Thalassemia
por: Farmakis, Dimitrios, et al.
Publicado: (2022)

Germline ERCC excision repair 6 like 2 ( ERCC6L2 ) mutations lead to impaired erythropoiesis and reshaping of the bone marrow microenvironment
por: Armes, Hannah, et al.
Publicado: (2022)

Deferasirox demonstrates a dose-dependent reduction in liver iron concentration and consistent efficacy across subgroups of non-transfusion-dependent thalassemia patients
por: Taher, Ali T, et al.
Publicado: (2013)

Storage of red blood cells in alkaline PAGGGM improves metabolism but has no effect on recovery after transfusion
por: de Bruin, Sanne, et al.
Publicado: (2022)

Dexamethasone and lenalidomide have distinct functional effects on erythropoiesis
por: Narla, Anupama, et al.
Publicado: (2011)

S273: LONG-TERM ERYTHROID RESPONSE DATA FROM PATIENTS (PTS) WITH NON-TRANSFUSION-DEPENDENT ΒETA-THALASSEMIA (NTDT) RECEIVING LUSPATERCEPT IN THE BEYOND TRIAL
por: Taher, Ali T., et al.
Publicado: (2023)

Kindlin-3 deficiency leads to impaired erythropoiesis and erythrocyte cytoskeleton
por: Szpak, Dorota, et al.
Publicado: (2023)

The transcriptomic landscape of normal and ineffective erythropoiesis at single-cell resolution
por: Doty, Raymond T., et al.
Publicado: (2023)

Iron Overload and Chelation Therapy in Non-Transfusion Dependent Thalassemia
por: Bou-Fakhredin, Rayan, et al.
Publicado: (2017)

Profile of Luspatercept in the Treatment of Anemia in Adults with Non-Transfusion-Dependent β-Thalassemia (NTDT): Design, Development and Potential Place in Therapy
por: Musallam, Khaled M, et al.
Publicado: (2023)

Splenectomy improves erythrocyte functionality in spherocytosis based on septin abundance, but not maturation defects
por: Cloos, Anne-Sophie, et al.
Publicado: (2023)

Safety and benefits of antenatal oral iron supplementation in low‐income countries: a review
por: Mwangi, Martin N., et al.
Publicado: (2017)

Drugs activating hypoxia-inducible factors correct erythropoiesis and hepcidin levels via renal EPO induction in mice
por: Nakai, Taku, et al.
Publicado: (2023)

Thalassaemia Intermedia: an Update
por: Taher, Ali T., et al.
Publicado: (2009)

Elevated CDKN1A (P21) mediates β-thalassemia erythroid apoptosis, but its loss does not improve β-thalassemic erythropoiesis
por: Liang, Raymond, et al.
Publicado: (2023)

Exjade® (deferasirox, ICL670) in the treatment of chronic iron overload associated with blood transfusion
por: Cappellini, Maria Domenica
Publicado: (2007)

Ferroportin inhibitor vamifeport ameliorates ineffective erythropoiesis in a mouse model of b-thalassemia with blood transfusions
por: Kalleda, Natarajaswamy, et al.
Publicado: (2023)

Four AAs increase DMT1 abundance in duodenal brush-border membrane vesicles and enhance iron absorption in iron-deprived mice
por: Woloshun, Regina R., et al.
Publicado: (2022)

Iron homeostasis governs erythroid phenotype in polycythemia vera
por: Bennett, Cavan, et al.
Publicado: (2023)

Fetal haemoglobin response to hydroxycarbamide treatment and sar1a promoter polymorphisms in sickle cell anaemia
por: Kumkhaek, Chutima, et al.
Publicado: (2008)

Increased levels of the inflammatory biomarker C-reactive protein at baseline are associated with childhood sickle cell vasocclusive crises
por: Krishnan, Suba, et al.
Publicado: (2010)

Transfer of 4-hydroxynonenal from parasitized to non-parasitized erythrocytes in rosettes. Proposed role in severe malaria anemia
por: Uyoga, Sophie, et al.
Publicado: (2012)

Risk factors for high cerebral blood flow velocity and death in Kenyan children with Sickle Cell Anaemia: role of haemoglobin oxygen saturation and febrile illness
por: Makani, Julie, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_u7bhrqmbp0n7ccuuccad3mn5rl